Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Hydralazine hydrochloride
Drug ID BADD_D01082
Description Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.[A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.[T691] Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779]
Indications and Usage Hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertension.[L8782] A combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failure.[L8785]
Marketing Status approved
ATC Code C02DB02
DrugBank ID DB01275
KEGG ID D01302
MeSH ID D006830
PubChem ID 9351
TTD Drug ID D0K1XK
NDC Product Code 58032-1004; 68259-1313; 51079-076; 55150-400; 55154-5689; 67877-292; 71872-7268; 72241-004; 72241-006; 75834-127; 75834-128; 17478-934; 31722-520; 31722-522; 43353-124; 50090-4641; 63629-8493; 63629-8494; 71209-017; 72572-265; 31722-521; 50228-183; 50228-184; 51079-074; 55154-7294; 63629-8495; 63629-8496; 63739-327; 70518-2551; 71209-016; 72241-005; 55154-9554; 62584-734; 63187-901; 67877-290; 70934-764; 71872-7145; 75834-126; 68259-1307; 69037-0047; 23155-002; 50228-182; 51079-075; 51662-1388; 55154-7293; 55154-7295; 62135-582; 62584-733; 0404-9994; 70518-0666; 70518-0832; 70934-571; 71205-091; 71335-1589; 0615-7973; 71872-7274; 76282-312; 55512-0010; 39822-0500; 50090-0137; 50228-185; 62135-579; 63629-8757; 63739-328; 64380-736; 67877-291; 71205-072; 71335-0482; 71335-1236; 0641-6231; 76282-311; 77771-184; 77771-185; 0904-6442; 62350-0080; 77777-116; 23155-004; 50090-0139; 50111-327; 50111-398; 51662-1376; 55154-6628; 63323-614; 64380-733; 64380-734; 0517-0901; 70518-1685; 71610-562; 59651-148; 66039-957; 72643-001; 31722-519; 43353-205; 50111-328; 55154-2082; 63629-5246; 63629-8497; 68071-2530; 68788-8087; 70518-0637; 71209-018; 71335-1685; 71335-9722; 71610-549; 71610-561; 76282-310; 0904-6441; 17511-102; 55289-133; 62135-581; 64380-735; 67544-657; 71335-0594; 71872-7050; 77771-182; 0904-6440; 0904-6443; 49452-3544; 23155-001; 43063-392; 50111-397; 61919-312; 62135-580; 63629-5696; 67877-293; 0404-9986; 68071-5285; 68084-447; 71335-0202; 76282-309; 77771-183; 65691-0088; 68554-0023; 23155-003; 55154-2083; 55154-5085
UNII FD171B778Y
Synonyms Hydralazine | Hydrallazin | Hydrazinophthalazine | Apressin | Nepresol | Hydralazine mono-Hydrochloride | Hydralazine mono Hydrochloride | mono-Hydrochloride, Hydralazine | Apressoline | Apresoline | Hydralazine Hydrochloride | Hydrochloride, Hydralazine
Chemical Information
Molecular Formula C8H9ClN4
CAS Registry Number 304-20-1
SMILES C1=CC=C2C(=C1)C=NN=C2NN.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agranulocytosis01.02.03.001--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Anxiety19.06.02.002--
Arthralgia15.01.02.001--
Chills15.05.03.016; 08.01.09.001--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Diarrhoea07.02.01.001--
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dyspnoea22.02.01.004; 02.11.05.003--
Dysuria20.02.02.002--
Eosinophilia01.02.04.001--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Haemoglobin decreased13.01.05.003--Not Available
Headache17.14.01.001--
Hepatitis09.01.07.004--Not Available
Hypoaesthesia17.02.06.023; 23.03.03.081--Not Available
Hypotension24.06.03.002--
Ileus paralytic07.02.05.001--Not Available
Lacrimation increased06.08.02.004--
Leukopenia01.02.02.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Muscle spasms15.05.03.004--
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neuropathy peripheral17.09.03.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Palpitations02.11.04.012--
Paradoxical pressor response24.08.02.003--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages